Worldwide, every two minutes one woman died because of cervical cancer. However, the study found that 85% of Chinese women in cervical cancer caused by human papillomavirus type 16/18. The study found no cervical HPV genotypes other regional differences. This information will in the future to assess the economic benefits of vaccines and to HPV-based cervical cancer screening to provide a scientific basis.

Statistics show that worldwide, 27 million women each year die of cervical cancer friends, it has become the second largest cause of death in women worldwide. According to research, called the human papillomavirus (HPV) cause cervical cancer virus is the culprit, of which HPV16 is the trigger type and 18 women, the most important type of uterine cancer, infection with the virus will cause the world at least seven per cent 10 or more cases of cervical cancer. HPV is a threat to the health and life of female friends, the “invisible killer.”

According to the latest released an updated completed research shows that in cervical cancer in Chinese women, most of HPV16 type and 18 from the trigger, and this finding was clearly above the global average. It is reported that the study was funded by the Chinese Medical Sciences / Peking Union Medical College Institute of Cancer Epidemiology Research Office, the Chinese Cancer Foundation Professor Qiao Youlin, director of international cooperation over the survey covering seven regions of China from 19 hospitals, 1,244 cervical cancer cases, the data gathering for China’s future cervical cancer prevention and treatment far-reaching.

Cervical cancer is a squamous cervical column occurred at the junction of tumor cells, the “culprit” of human papillomavirus (HPV) in cervical intraepithelial self-replicating and thus escape the human immune system’s surveillance, leading to cancer. According to experts, “from women infected with HPV to develop cervical precancerous lesions and invasive cervical cancer is from about 10 years or several decades, therefore, on the early diagnosis of cervical lesions and cervical treatment is to reduce the current Cancer incidence and mortality of important measures. ”

Experts agree that the global pharmaceutical companies GlaxoSmithKline’s cervical cancer vaccine developed over many years, in parts of the virus infection and replication, resulting in highly efficient antibodies to maximize the prevention of the most common cancer-causing human papilloma virus type-induced cervical cancer and precancerous lesions. It is reported that the vaccine has been in the 27 EU member states, Australia, the Philippines and Macau and other countries and regions listed.